ABVC BioPharma
ABVC
9 hedge funds and large institutions have $421K invested in ABVC BioPharma in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
12% more capital invested
Capital invested by funds: $377K → $421K (+$44.1K)
0.02% more ownership
Funds ownership: 0.18% → 0.2% (+0.02%)
0% more funds holding
Funds holding: 9 → 9 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$17.8K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$15.1K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.57K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.78K |
| 5 |
BlackRock
New York
|
+$1.03K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.69K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$714 |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$32 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $248K | +$8.57K | +1,200 | +3% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $87.8K | – | – | – |
|
|
3
BlackRock
New York
| $27.3K | +$1.03K | +144 | +3% |
|
|
4
Two Sigma Investments
New York
| $15.9K | +$17.8K | +2,490 | New |
|
|
TSS
5
Two Sigma Securities
New York
| $13.5K | +$15.1K | +2,107 | New |
|
6
Northern Trust
Chicago,
Illinois
| $11.8K | – | – | – |
|
|
7
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $8.77K | +$2.78K | +389 | +39% |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $8K | -$714 | -100 | -7% |
|
9
Wells Fargo
San Francisco,
California
| $78 | – | – | – |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$2.69K | -428 | Closed |
|
|
11
Bank of America
Charlotte,
North Carolina
| – | -$32 | -5 | Closed |
|
ABVC Hedge Fund Activity: Q1 2023 in Review
9 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q1 2023, worth a combined $421K — up 12% from $377K a quarter earlier.
Fund positioning in ABVC was balanced in Q1 2023: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 1 trimmed.
The largest buyer was Two Sigma Investments, opening a new position worth an estimated $17.8K. The largest seller was UBS Group, exiting entirely with an estimated $2.69K sold.
- 9 institutional investors held ABVC BioPharma (ABVC) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $421K of ABVC BioPharma stock for Q1 2023, up 12% quarter-over-quarter.
- 2 funds opened new ABVC BioPharma positions in Q1 2023 and 2 closed out, a net change of 0 holders.
- The largest ABVC BioPharma buyer in Q1 2023 was Two Sigma Investments, an estimated $17.8K added.
- The largest ABVC BioPharma seller in Q1 2023 was UBS Group, an estimated $2.69K sold.
Based on aggregated 13F filings for Q1 2023.